Questions About Cancer? 1-800-4-CANCER
  • Posted: 12/10/2012
NCI Cancer Center News

Fox Chase study finds new small molecule inhibitor could be a safe and first-line treatment for metastatic breast cancer

Previous research has shown that a family of genes, proteins and enzymes called the uPA system (for urokinase plasminogen activator) plays an active role in different facets of cancer's biology, including tumor cell invasion, the spread of metastases, and the growth of a primary tumor. Mesupron is a new small molecule inhibitor, taken as a pill, that inhibits the uPA system. The results from a recent phase II clinical study from the Fox Chase Cancer Center suggest that the drug could be a safe and first-line treatment that extends progression-free survival for metastatic breast cancer patients, when combined with the chemotherapeutic drug Capecitabine.

Click here to read full press release.

###

NCI comprehensive cancer centers logoAmong the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.